We aim to quantify whole‐brain tissue‐property changes in patients with magnetic resonance imaging (MRI)–negative pharmacoresistant focal epilepsy by three‐dimensional (3D) magnetic resonance fingerprinting (MRF). Click to show full abstract
We aim to quantify whole‐brain tissue‐property changes in patients with magnetic resonance imaging (MRI)–negative pharmacoresistant focal epilepsy by three‐dimensional (3D) magnetic resonance fingerprinting (MRF).
               
Click one of the above tabs to view related content.